tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002

Story Highlights
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Percheron Therapeutics ( (AU:PER) ) has issued an update.

Percheron Therapeutics has announced the final results of its Phase I clinical trial for HMBD-002. The results of this trial are significant for the company’s operations and may influence its positioning in the pharmaceutical industry, although the inherent risks and uncertainties in drug development are acknowledged.

The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Average Trading Volume: 3,152,884

Technical Sentiment Signal: Sell

Current Market Cap: A$10.87M

Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1